Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. Zusätzlich bieten wir Ihnen Somatostatin Receptor 2 Antikörper (83) und Somatostatin Receptor 2 Proteine (7) und viele weitere Produktgruppen zu diesem Protein an.
Showing 7 out of 11 products:
SSTR2 was significantly hypermethylated in colorectal cancer tissues when compared with adjacent normal colorectal tissues.
This study investigated the presence of progenitor/stem cells in non-functioning pituitary tumors (NFPTs) and tested the efficacy of dopamine receptor type 2 (DRD2 (zeige DRD2 ELISA Kits)) and somatostatin receptor type 2 (SSTR2) agonists to inhibit in vitro proliferation
expression of MDM2 (zeige MDM2 ELISA Kits), somatostatin (zeige SST ELISA Kits) receptor 2A, and PD-L1 (zeige CD274 ELISA Kits) in follicular dendritic cell sarcoma
Combination treatment increased both SSTR2 and SSTR5 (zeige SSTR5 ELISA Kits) mRNA and protein levels in DU-145 cells. The data suggest that this combination therapy may be a good candidate for patients with advanced metastatic Prostate cancer (PCa (zeige FLVCR1 ELISA Kits)) do not respond to androgen deprivation.
although the limited number of cases with adequate term follow-up, SSTR (zeige SSTR3 ELISA Kits)-2A expression could be a prognostic factor and somatostatin (zeige SST ELISA Kits) analogs therapeutic candidate for SmCCs of the bladder as these tumors show high percentage of SSTR (zeige SSTR3 ELISA Kits)-2A expression
SSTR2 expression was tested in GH-secreting adenomas from 60 patients with acromegaly who had undergone pituitary surgery, 36 of whom had received octreotide with varying levels of response. Its expression was not correlated with baseline or post-octreotide GH or IGF-1 (zeige IGF1 ELISA Kits) levels or tumor volume.
Filamin-A (zeige FLNA ELISA Kits) is required to mediate SSTR2 effects in pancreatic neuroendocrine tumours
Data showed that the distribution of somatostatin (zeige SST ELISA Kits) receptor (SSTR (zeige SSTR3 ELISA Kits)) subtypes among the 199 pancreatic neuroendocrine tumors (PNETs) was: SSTR2 (54.8%), SSTR1 (zeige SSTR1 ELISA Kits) (53.3%), SSTR4 (zeige SSTR4 ELISA Kits) (51.8%), SSTR5 (zeige SSTR5 ELISA Kits) (33.7%), and SSTR3 (zeige SSTR3 ELISA Kits) (28.6%).
SSTR2 promoter hypermethylation might be associated with the risk and progression of laryngeal squamous cell carcinoma in males.
VPA was observed to stimulate the expression of somatostatin receptor type 2 (SSTR2).
Loss of sst2 from pancreatic tissues activates PI3K signaling via AKT (zeige AKT1 ELISA Kits), leading to activation of NF-kappaB (zeige NFKB1 ELISA Kits), amplification of oncogenic KRAS signaling, increased expression of CXCL16 (zeige CXCL16 ELISA Kits), and pancreatic tumor formation.
The expression and localization of the three receptors (SSTR3 (zeige SSTR3 ELISA Kits)-SSTR5 (zeige SSTR5 ELISA Kits)) in wild-type (WT), single-knockout (SSTR1 (zeige SSTR1 ELISA Kits) KO) and double-knockout SSTR1 (zeige SSTR1 ELISA Kits)/SSTR2 (DKO) mice, are reported.
SST2 expression protects against gentamicin-induced auditory hair cell loss in the mammalian inner ear.
Knock-down of SSTR2 leads to loss of pluripotency in murine embryonic stem cells.
Inhibition of the Sstr2 receptor reversed the anticonvulsant effect mediated by cortistatin-14 (zeige CORT ELISA Kits).
OCT-P407 induces mRNA expression of SSTR-2 and caspase-3 and decreases that of VEGF in mice.
The study encourages the use of liver tissue SSR2 (zeige SSR2 ELISA Kits) protein and mRNA as a reliable tumor marker for liver cancer
when activated by SST (zeige SST ELISA Kits)-14, SSTR2A internalizes and recycles via the Golgi, which requires ECE-1 (zeige ECE1 ELISA Kits) degradation of SST (zeige SST ELISA Kits)-14 and receptor dissociation from beta-arrestins
Findings suggest that somatostatin (zeige SST ELISA Kits) and its receptors (SSTR2 and SSTR5 (zeige SSTR5 ELISA Kits)) are important markers in the regulation and development of Sertoli cell.
The aim of this study was to validate an animal model expressing SSTR2 and to correlate the immunohistochemical (IHC) analysis with (18)F-FDG (zeige SMUG1 ELISA Kits) and (68)Ga-DOTATOC uptake in vivo.
Follicle-stimulating hormone regulates the SSTR2 protein expression in bovine granulosa cells.
SRIF (zeige SST ELISA Kits) can inhibit testosterone secretion through the sst2A receptor; local inhibitory action of SRIF (zeige SST ELISA Kits) is probably autocrine & might involve testosterone-induced increase of sst2 receptor expression in immature Leydig cells [SST2A]
Data demonstrate that urotensin II (zeige UTS2 ELISA Kits) and urotensin II-related peptide directly activate somatostatin (zeige SST ELISA Kits) receptors 2 and 5 and thus mimic the effect of somatostatin (zeige SST ELISA Kits) on its cognate receptors.
Somatostatin (zeige SST ELISA Kits) directly promoted spontaneous contractions of the circular muscle of macaque intestine via mediation of SSTR2 in myenteric nerve plexus between the longitudinal and the circular muscle.
5-HT(1A (zeige HTR1A ELISA Kits)), SST (zeige SST ELISA Kits)(1), and SST (zeige SST ELISA Kits)(2) receptors mediate nonadrenergic IPSPs in the noncholinergic (VIP (zeige Vip ELISA Kits)) secretomotor neurons of the submucous plexus of the guinea pig ileum.
Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. The biologic effects of somatostatin are probably mediated by a family of G protein-coupled receptors that are expressed in a tissue-specific manner. SSTR2 is a member of the superfamily of receptors having seven transmembrane segments and is expressed in highest levels in cerebrum and kidney.
, somatostatin receptor type 2
, somatostatin receptor subtype 2
, somatotropin release-inhibiting factor receptor
, somatostatin receptor 2
, somatostatin type 2 receptor
, somatostatin receptor type 2-like